Research Abstract
Failure of somatostatin to inhibit tolbutamide-induced insulin secretion in patients with insulinomas: a possible diagnostic tool.
Lorenzi M, Gerich JE, Karam JH, Forsham PH
The Journal of clinical endocrinology and metabolism
Jun 1, 1975
Sources
1 min read
AI Summary
Key Findings
0:00 / 0:00
0:00 / 0:00
Abstract
The effects of somatostatin on tolbutamide-stimulated insulin release were studied in 4 patients with insulin-producing tumors of the pancreas and in 6 normal subjects. In contrast to its effective inhibition of insulin release in normal subjects, somatostatin, without exception, failed to inhibit tolbutamide-induced insulin release in the patients with pancreatic beta-cell tumors. This differential effect of somatostatin may prove useful in the diagnosis of insulin-producing tumors of the pancreas.
External References
- PubMed ID:
- 166088
Comments
Sign in or create a free account to join the conversation.
Sign in to commentBe the first to comment.